KUALA LUMPUR, Malaysia, Oct. 1, 2025 /PRNewswire/ — The Minister of Health, Y.B. Datuk Seri Dr. Dzulkefly Ahmad today announced that the selection and evaluation process of finding MHTC new Chief Executive Officer (CEO) is officially concluded with the appointment of Encik Suriaghandi Suppiah effective 29 September 2025.

Suriaghandi’s career is marked by his ability to lead transformation initiatives, strengthen operations, and drive sustainable growth across diverse sectors. Most recently, he has served as Healthcare Advisor to the Employees Provident Fund (EPF), where he played a pivotal role in shaping EPF’s Healthcare Investment Strategy. In addition, as a Board Member of the National Sports Council, he led significant reforms and was instrumental in launching the Olympic Sports Development Program.

Suriaghandi’s leadership journey spans several senior roles, including Group Chief Operating Officer at KPJ Healthcare Berhad, Consultant at Vamed Healthcare Services, and Director of Property Management at Savills Malaysia. His impactful contributions also extend to Khazanah Nasional Berhad and Parkway Group Healthcare, where he championed strategic investments, business expansion, and organizational transformation.

Welcoming his appointment, YB Minister of Health, Dr. Dzulkefly Ahmad, stated: “Malaysia’s healthcare ecosystem continues to grow in strength, both domestically and internationally. With the upcoming Malaysia Year of Medical Tourism 2026 (MYMT2026), we are committed to positioning the nation as a global leader in healthcare tourism destination. His leadership at MHTC will strengthen our efforts to expand access, attract international patients, and enhance Malaysia’s reputation as a trusted destination for quality and affordable healthcare.”

In his new role, Suriaghandi Suppiah is expected to lead the next phase of MHTC’s mission in strengthening Malaysia’s position as the world’s leading healthcare travel destination, while upholding the highest standards of care, accessibility, and value for patients globally.

For media inquiries and further information, please contact:

Mohamad Shahizam Fauzi                                              
Head, Communications
+603 8776 6168                 
shahizam.f@mhtc.org.my

Muhammad Rasydan Ma’at                                                         
Asst. Manager, Communications
+603 8776 6168     
rasydan.m@mhtc.org.my

About Malaysia Healthcare Travel Council

Malaysia Healthcare Travel Council (MHTC), established in 2009 under the purview of the Ministry of Health (MOH) Malaysia, is entrusted with developing and nurturing the “Malaysia Healthcare” brand. MHTC enhances, coordinates, and promotes Malaysia’s healthcare travel industry by fostering industry collaborations and building valuable public-private partnerships both domestically and internationally. With 80 member hospitals nationwide, MHTC continues to elevate the healthcare travel ecosystem through strong branding, seamless patient experiences, and strategic market initiatives. In line with these efforts, MHTC is spearheading the Malaysia Year of Medical Tourism (MYMT) 2026, the nation’s first dedicated year to celebrate and advance healthcare travel. MYMT 2026 serves as a milestone initiative to showcase Malaysia’s world-class healthcare offerings, strengthen its position as the premier global healthcare destination, and highlight the industry’s significant contribution to the national economy.

More information can be found at https://www.mhtc.org.my/ 

MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38^th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona from 4 – 8 October 2025.

Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to showcase our late-stage and next generation development programs and innovations in MedTech at EANM – the largest gathering of nuclear medicine professionals worldwide. Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC^[1], the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC^[2]. Telix will host a sponsored symposium on CAIX^[3] and FAP^[4] targeting theranostics, and abstracts will also be presented from Telix’s pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global access to innovative cancer imaging and therapy.”

As in previous years, Telix will again support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and an inspiring educator.

Visit booth #78 to explore opportunities for collaboration with Illuccix® (kit for the preparation of gallium-68 gozetotide injection) Telix’s commercial PSMA-PET^[5] imaging agent in Europe, our industry-leading theranostic pipeline and medical technologies, including the SENSEI® miniature drop-in gamma probe, QDOSE® dosimetry software and artificial intelligence (AI).

EANM presentation details are as follows (all times CEST): 

Sponsored Symposium

Title: From pan-tumor innovation to theranostic precision. Fibroblast activation protein (FAP) and carbonic anhydrase IX (CAIX) case studies
Date & Time: 5-Oct-25, 13:15 – 14:45
Location: Room 116, CCI Barcelona
Chair: A. Italiano, Institut Bergonié (University of Bordeaux) & Gustave Roussy (Villejuif), France
Agenda:
Agnostic approaches in oncology and drug development: setting the stage

• A. Italiano

Introduction to FAP and diagnostic applications

• Y. Mori, Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Germany

FAP-targeted Radiopharmaceutical Therapy: A Promising Avenue in Radiomolecular Oncology

• R. Baum, CURANOSTICUM Wiesbaden-Frankfurt MVZ, Center for Advanced Radiomolecular Precision Oncology, DKD HELIOS Klinik, Wiesbaden, Germany

Clinical Applications of CAIX

• D. Oprea-Lager, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands

Therapeutic potential of CAIX inhibitors

• C. Suárez, Vall d’Hebron University Hospital, Barcelona, Spain

Oral presentations

Title: Investigating FAP binding of the dimeric DOTAGA.Glu.(FAPI)₂ (TLX400) labelled with terbium-161 in ovarian cancer models incorporating the tumor microenvironment^[6]Date and Time: 5-Oct-25, 15:10  – 15:20
Presenter: I. Primac, SCK CEN, Mol, Belgium
Abstract #: OP-150

Title: Reactive evaluation – a novel alternative to transfer learning to handle multi-centric variations in prostate cancer cohorts
Date and Time: 6-Oct-25, 09:45 – 09:55
Presenter: L. Papp, Medical University of Vienna, Vienna, Austria
Abstract #: OP-352

Title: Tumor-stroma dynamics define FAP optimum imaging and therapeutic windows in the management of glioblastoma
Date and Time: 6-Oct-25, 16:00 – 16:10
Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland
Abstract #: OP-417

Title: Synergistic anti-tumor effects of ²²⁵Ac-DOTA-girentuximab (TLX252) combined with DNA damage response inhibitors in CAIX-positive renal cancer
Date and Time: 7-Oct-25, 08:10 – 08:20
Presenter: Z. Cao, Olivia Newton-John Cancer Research Institute and Austin Health, Heidelberg, Australia
Abstract #: OP-516

Title: Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET/CT imaging: a preliminary study
Date and Time: 7-Oct-25, 08:50 – 09:00
Presenter: D. Han, Telix Pharmaceuticals, Sydney, Australia
Abstract #: OP-529

Title: Combining CAIX-targeted radionuclide therapy with immune checkpoint inhibitors: which inhibitor and when?
Date and Time: 7-Oct-25, 09:00 – 09:10
Presenter: S. Kleinendorst, RadboudUMC, Nijmegen, Netherlands
Abstract #: OP-521

Title: ProstACT Global: A Phase 3 study of lutetium (Lu177) rosopatamab tetraxetan (TLX591) plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer
Date and Time: 7-Oct-25, 15:40 – 15:50
Presenter: J. Piulats, Bellvitge Biomedical Research Institute, Barcelona, Spain
Abstract #: OP-674

Title: Preliminary assessment of ⁸⁹Zr-Girentuximab (TLX250-CDx) excretion and radiation protection in ccRCC patients undergoing PET/CT imaging
Date and Time: 7-Oct-25, 17:35 – 17:45
Presenter: A. Piai, IRCCS Ospedale San Raffaele, Milan, Italy
Abstract #: OP-706

Title: IPAX-Linz: Phase 2 study to evaluate safety, tolerability, and preliminary efficacy of carrier-added ¹³¹I-IPA (TLX101) in patients with recurrent GBM concomitantly to 2nd line re-irradiation
Date and Time: 8-Oct-25, 08:00 – 08:10
Presenter: J. Pichler, Kepler University Hospital, Linz, Austria
Abstract #: OP-778

Title: Safety of radioligand therapy with ¹⁷⁷Lu-FAPi-Dimer (TLX400) with dose escalation in a clinical setting⁶
Date and Time: 8-Oct-25, 08:10 – 08:20
Presenter: J. Urena Poch, Rostock University Medical Center, Rostock, Germany
Abstract #: OP-779

Title: Immunomodulation of the tumor microenvironment by ²²⁵Ac-DOTA-girentuximab (TLX252) in a syngeneic murine tumor mode
Date and Time: 8-Oct-25, 09:10 – 09:20
Presenter: R. Ladjohounlou, University of Wisconsin, Madison, WI, U.S.
Abstract #: OP-767

Poster presentations

Title: Preclinical development of ¹⁶¹Tb-DOTA-HYNIC-panPSMA and comparison with ¹⁷⁷Lu-DOTA-HYNIC-panPSMA, ¹⁶¹Tb-DOTA-J591 and ¹⁷⁷Lu-DOTA-J591 (TLX591)
Presenter: C. Morgat, CHU Bordeaux, Bordeaux, France
Abstract #: EP-0069

Title: CAIX-targeting for radioimmunotherapy in triple-negative breast cancer
Presenter: A. Ivashkevich, Telix Pharmaceuticals, Melbourne, Australia
Abstract #: EP-0130

Title: Prostate cancer detection with ^99mTc-HYNIC-iPSMA SPECT: The Australian experience
Presenter: P. Tually, Spartan First Imaging, Kalgoorlie, Australia
Abstract #: EP-0353

Title: Potential of ⁸⁹Zr-girentuximab (TLX250-CDx) PET/CT for the routine clinical management of patients with suspicious, unspecified renal lesions (real-world experience)
Presenter: S. Rasul, Medical University of Vienna, Vienna, Austria
Abstract #: EP-0528

Title: Improving clinical management of von Hippel-Lindau Syndrome with ⁸⁹Zr-girentuximab (TLX250-CDx) PET Imaging (real-world experience)
Presenter: F. Gelardi, IRCCS Ospedale San Raffaele, Milan, Italy
Abstract #: EP-0534

Title: IPAX-2: Phase 1 safety and dose finding study of ¹³¹I-IPA (TLX101) plus standard of care in patients with newly diagnosed glioblastoma
Presenter: J. Pichler, Kepler University Hospital, Linz, Austria
Abstract #: EP-0785

Title: ¹⁷⁷Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer
Presenter: Y. Omar, Misr Radiology Center, Cairo, Egypt
Abstract #: EP-0810

Title: Robust self-supervised deep learning reconstruction model for reduced ⁸⁹Zr-girentuximab (TLX250-CDx) PET scan time
Presenter: C. Pain, Monash Biomedical Imaging, Melbourne, Australia
Abstract #: EP-0978

Title: Preclinical evaluation of DOTAGA.PEG₂.Glu.(FAPI)₂, a FAP dimeric inhibitor, for developing theranostic radiotracers in FAP-positive malignancies⁶
Presenter: N. Kumar, Bern University Hospital, Bern, Switzerland
Abstract #: EPS-013

Title: Intraindividual tumor dosimetry of monomer ⁹⁰Y-FAPI-46 vs dimer ⁹⁰Y-DOTAGA-Glu-(FAPI)₂ FAP radioligand therapy of advanced stage solid tumors
Presenter: P. Fragoso Costa, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Abstract #: EPS-190

Title: Therapeutic potential of DOTAGA.Glu.(FAPI)₂ (TLX400) and DO3A.Glu.(FAPI)₂ with human dosimetry extrapolation for 177-lutetium and 161-terbium⁶
Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland
Abstract #: EPS-193

Rhine Pharma presentations

Title: Impact of formulation buffers on the radiolysis and stability of RHN001-Tx (¹⁸⁸Re-PSMA)
Date and Time: 6-Oct-25, 10:45 – 10:55
Presenter: S. Mdanda, Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, South Africa
Abstract #: OP-349

Title: Clinical trial protocol for RHINO trial: Prospective single-center Phase 1/2 study of RHN001-Dx/Tx in men with PSMA-positive prostate cancer post adjuvant androgen deprivation therapy and/or taxane-based chemotherapy
Date and Time: 8-Oct-25, 09:20 – 09:30
Presenter: H. Ndlovu, NuMeRI, Pretoria, South Africa
Abstract #: OP-825

Title: A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx (^99mTc-PSMA) in correlation with tumor burden and its implications for theranostic use
Date and Time: 8-Oct-25, 11:05 – 11:15
Presenter: S. Martlbauer, University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany
Abstract #: OP-881

Title: A calibration workflow for accurate quantification of rhenium-188 in RHN001-Tx for theranostic applications
Presenter: M. Qebetu, NuMeRI, Pretoria, South Africa
Abstract #: EP-0942

Title: Quantitative ^99mTc-SPECT/CT dosimetry using a CZT gamma camera: Initial clinical experience
Presenter: K. Ramonaheng, NuMeRI, Pretoria, South Africa
Abstract #: EP-1116

Title: Production optimization and quality control testing of RHN001-Tx (¹⁸⁸Re-PSMA) per GMP standards
Presenter: S. Sibiya, NuMeRI, Pretoria, South Africa
Abstract #: EP-1200

About Rhine Pharma

Rhine Pharma™ is a wholly-owned subsidiary of Telix. Its mission is to expand global access to innovative cancer imaging and therapy by leveraging the unique benefits of technetium-99m (^99mTc) and rhenium-188 (¹⁸⁸Re).  Visit www.rhine-pharma.com for further information.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. Food and Drug Administration (FDA). Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (^99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s SENSEI® drop-in gamma probe is registered with the Australian Therapeutic Goods Administration (TGA) and with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. Telix’s QDOSE® dosimetry software has received 510(k) clearance from the FDA and is CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices 

Cautionary Statement Regarding Forward-Looking Statements  

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.  

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.  

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.  

Trademarks and Trade Names

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.  

©2025 Telix Pharmaceuticals Limited. All rights reserved.

SYDNEY, Oct. 1, 2025 /PRNewswire/ — SKINGRAPHICA is the first luxury skincare line for skin art, rewriting the rules of the multi billion-dollar tattoo industry. This Australian company has created a scientifically advanced, dermatologically tested, and performance-led skincare system specifically for tattooed skin.

The brand’s formulations are a world first, developed using a custom-built AI engine trained on skin science, biochemistry, and tattoo ink behavior, with human formulators finessing the final products. This innovative partnership has created a full line of products, including a world-first tattoo restoration cream called LUME.

Unlike most skincare, which is not designed for the altered structure and pigment of tattooed skin, SKINGRAPHICA uses targeted, stage-specific formulations. Tattoos live in the dermis, and general skincare often contains ingredients that are not Ink-Safe™. These include strong resurfacing acids, high-strength retinoids, and harsh peels, which can thin the skin, accelerate cell turnover, and blur or mute tattoo color. SKINGRAPHICA avoids these harsh, ink-compromising actives, engineering every formula with Ink-Safe™ biochemistry.

The brand’s core products address the full lifecycle of a tattoo:

• PRIME ($254AUD / $165USD, 30ml): A lightweight serum with ceramides, ectoin, and panthenol to hydrate and protect the skin barrier before a tattoo.
• LOCK ($276AUD / $179USD 50ml): A cream that supports newly tattooed skin by securing pigment, restoring barrier lipids, and reducing discomfort with ingredients like centella triterpenes and squalane.
• SHIELD ($239AUD / $155USD, 50ml): This daily moisturiser uses the TattooGuard™ UV-Defence System to protect against UV, blue light, and pollution, helping to slow pigment fading.
• LUME ($386AUD / $255USD 30ml | $530AUD / $385USD 50ml): A breakthrough dual-action formula that is infused with light-diffusing agents, gentle renewing actives, and nourishing emollients, it smooths and conditions skin without compromising pigment. It is especially beneficial for tattoos five years or older, helping them appear more luminous and vivid.

Founded by Mat Baxter and artist Mikael Ramgard, SKINGRAPHICA bridges artistry and science to represent a new class of tattoo-dermatological adjuncts. With 6.6 million Australians having tattoos, and 39% of Gen Z having one, SKINGRAPHICA is meeting a clear customer need that has been ignored major beauty retailers. The brand is launching with a direct-to-consumer model, shipping to over 50 countries from October 1, 2025.

Media Contact: 
Hollie Smith
hollie@shapr.com.au 

• Provides AI ASIC solutions for fabless companies and device manufacturers
• New order volume surges: KRW 5.7 billion (2020), KRW 28.6 billion (2022), KRW 100 billion (2024)

SEOUL, South Korea, Oct. 1, 2025 /PRNewswire/ — SEMIFIVE, a global leader in custom AI semiconductor (ASIC) design, announced today that it received preliminary approval for listing on the KOSDAQ market from the Korea Exchange on September 30. Samsung Securities and UBS are serving as joint lead underwriters.

Founded in 2019, SEMIFIVE has been providing comprehensive end-to-end AI ASIC solutions to a wide range of clients—including fabless companies and OEM device manufacturers—covering everything from AI chip specification and logic design to full production support.

The global semiconductor industry is undergoing a significant transformation. As Moore’s Law approaches its limits and the cost of AI accelerators rises sharply, demand is rapidly shifting away from general-purpose chips such as GPUs and CPUs toward customized ASICs. Capitalizing on this trend, SEMIFIVE’s new order volume has surged nearly 17-fold in just four years, increasing from KRW 5.7 billion in 2020 to KRW 28.6 billion in 2022, and reaching KRW 100 billion in 2024.

Industry experts attribute this growth to SEMIFIVE’s platform-based design strategy. The company leverages its proprietary semiconductor design platform to maximize development efficiency in both time and cost, while also offering turnkey E2E (End-to-End) solutions that support the entire chip development lifecycle—from design to mass production.

SEMIFIVE’s AI ASIC business model is designed for sustainable growth: as development projects transition into mass production, revenue growth accelerates. With multiple projects currently entering the production phase, the company anticipates that its growth trajectory will gain further momentum.

“In the rapidly evolving AI semiconductor market, shortening time-to-market is key to securing competitiveness,” said a SEMIFIVE spokesperson. “SEMIFIVE is one of the few companies capable of supporting the entire AI ASIC development cycle swiftly and in accordance with customer requirements.”

Building on its success in Korea, SEMIFIVE has accelerated its global expansion since 2025, securing consecutive AI semiconductor design projects from clients in the U.S., China, and Japan. Proceeds from the upcoming IPO will be used to ensure the smooth execution of SEMIFIVE’s growing pipeline of mass-production projects, accelerate R&D in advanced design technologies such as chiplets, and further expand its global operations while strengthening the development of engineering talent.

“Our vision is to lead innovation in chip design for the era of custom AI semiconductors, just as foundries drove breakthroughs in manufacturing during the age of general-purpose CPUs and GPUs,” said Brandon Cho, CEO and co-founder of SEMIFIVE. “The surge in new orders signals a new wave of innovation in design. Through this IPO, SEMIFIVE will proactively address the growing demand for AI ASICs while scaling our capabilities to grow alongside global semiconductor leaders.”

Media Contact
Robin Kim, Senior Director, robin.kim@semifive.com

About SEMIFIVE
SEMIFIVE is the pioneer of platform based SoC design, working with customers to implement innovative ideas into custom silicon in the most efficient way. Our SoC platforms offer a powerful springboard for new chip designs and leverage configurable domain-specific architectures and pre-validated key IP pools. We offer comprehensive spec-to-system capabilities with end-to-end solutions so that custom SoCs can be realized faster, with reduced cost and risks for key applications such as data center or AI-enabled IoT. With a strong partnership with Samsung Foundry as a leading SAFE^TM DSP partner, as well as the larger ecosystem, SEMIFIVE provides a one-stop shop solution for any SoC design needs. For more information, please visit www.semifive.com.